REPL: Bull Flag detected on 4 Sep 2026

REPL is forming a bull flag pattern with excellent structure and volume characteristics. At $15.29, the stock is trading between key support at $14.90 and resistance at $16.15. Structure scores 15.0/15 reflecting crisp consolidation after a strong 54.91% rally over three months. The breakout score of 9.9/13 indicates moderate momentum confirmation, while volume score of 12.0/12 shows institutional participation. RSI at 58.97 sits in neutral territory—neither overbought nor oversold. Overall pattern quality scores 74.9/98, with a win probability of 73.53%, suggesting a high-conviction setup ready to pivot higher.

Replimune won FDA accelerated approval for Tudriqev on August 7, 2026, marking a transformational regulatory milestone. This is the company's first product on the market after the FDA had turned down two earlier applications over clinical data-quality concerns. The catalyst triggered broad analyst upgrades: BMO Capital raised its price target to $20 from $16 and maintained an Outperform rating, while Wedbush upgraded to Outperform from Neutral with a price target of $19, up from $12. Replimune raised $150 million in equity offering, strengthening balance sheet for commercial launch. The pattern is forming post-catalyst consolidation as market digests approval and pricing dynamics. Earnings are estimated for November 8, 2026, providing near-term visibility on commercial traction.

A successful breakout above $16.15 resistance would target $15.79 on a conservative basis, though measured move potential extends higher given post-FDA-approval tailwinds. Volume confirmation is critical—current volume ratio of 0.38x average suggests the breakout will require above-average participation to sustain. The invalidation level sits at key support of $14.90; a close below this would signal pattern failure and suggest profit-taking ahead of earnings. The 73.53% win probability indicates historical similar setups broke out successfully roughly three-quarters of the time, favoring upside resolution.

Multiple litigation risks threaten near-term momentum. A securities lawsuit was filed focusing on FDA disclosure issues surrounding the RP1 approval process, with the company asking the court to dismiss the case on August 27, 2026. Settlement risk or adverse ruling could trigger sharp reversals. Additionally, commercial execution risk is material—Tudriqev faces established competitors in melanoma, and real-world uptake remains unproven. Volume running at only 38% of 20-day average signals weak conviction into this setup; the low volume ratio suggests breakout could face liquidity challenges. Beta of 0.68 provides some downside cushion but limits participation in sector rallies. With earnings November 8, guidance and early sales data will be critical; any disappointing numbers could invalidate the technical setup quickly.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.